Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the Allegro Phase 2b/3 Study

September 2023 in “ Dermatology and therapy ”

Diamant Thaçi, Christos Tziotzios, Taisuke Ito, Justin Ko, Ayşe Serap Karadağ, Hong Fang, Roger Edwards, Gianluca Bonfanti, Robert Wołk, Helen Tran, Ernest Law

alopecia areata ritlecitinib JAK3 inhibitor TEC family kinase inhibitor hair loss profiles Patient Global Impression of Change Patient Satisfaction with Hair Growth AA PGI-C P-Sat

TLDR Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

The document summarizes a post hoc analysis of the ALLEGRO phase 2b/3 trial involving 655 patients with alopecia areata (AA), which aimed to identify hair loss profiles and assess the efficacy of ritlecitinib, an oral JAK3 and TEC family kinase inhibitor. The study identified five distinct hair loss profiles and found that ritlecitinib was significantly more effective than placebo in improving hair growth and patient satisfaction after 24 weeks of treatment, regardless of the patient's baseline hair loss profile. The efficacy was measured by the Patient Global Impression of Change (PGI-C) and Patient Satisfaction with Hair Growth (P-Sat), with higher odds ratios for positive responses in the ritlecitinib groups compared to placebo. The study, sponsored by Pfizer Inc., suggests ritlecitinib is an effective treatment for AA across different hair loss profiles, although it acknowledges the limitation of the 24-week study duration.

View this study on link.springer.com →

Discuss this study in the Community →

Cited in this study

13 / 13 results

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , May 2022 in “The New England Journal of Medicine”

Baricitinib was effective in treating alopecia areata in two major trials.

research Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata

134 citations , August 2020 in “Experimental dermatology”

Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.

research Targeting the Janus Kinase Family in Autoimmune Skin Diseases

124 citations , October 2019 in “Frontiers in Immunology”

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

research Treatment of Alopecia Areata: An Australian Expert Consensus Statement

95 citations , November 2018 in “Australasian journal of dermatology”

Alopecia areata treatment varies, with no optimal method established yet.

research Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata

53 citations , July 2018 in “Drug design, development and therapy”

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , January 2017 in “Journal of The American Academy of Dermatology”

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

research Health-Related Quality of Life Among Patients With Alopecia Areata: A Systematic Review

95 citations , October 2016 in “Journal of The American Academy of Dermatology”

People with alopecia areata, a skin disease, generally have a poor quality of life, especially if more of their scalp is affected.

research The Autoimmune Basis of Alopecia Areata: A Comprehensive Review

162 citations , February 2015 in “Autoimmunity reviews”

Alopecia areata is caused by the immune system attacking hair follicles.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations , August 2014 in “Nature medicine”

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

research Transcriptional Profiling in Alopecia Areata Defines Immune and Cell Cycle Control Related Genes Within Disease-Specific Signatures

61 citations , September 2010 in “Genomics”

The study found that immune responses disrupt hair growth cycles, causing hair loss in alopecia areata.

research Alopecia Areata Update

244 citations , February 2010 in “Journal of the American Academy of Dermatology”

The document says current treatments for alopecia areata do not cure or prevent it, and it's hard to judge their effectiveness due to spontaneous remission and lack of studies.

research Alopecia Areata Update

391 citations , February 2010 in “Journal of The American Academy of Dermatology”

Half of people with Alopecia Areata may see hair regrowth within a year without treatment, but recovery is unpredictable.

research Familial Aggregation of Alopecia Areata

295 citations , April 2006 in “Journal of the American Academy of Dermatology”

Alopecia areata, a common autoimmune hair loss condition, often runs in families.

2 / 2 results

research Baseline Distribution of Eyebrow and Eyelash Loss by Severity of Scalp Hair Loss in Phase 3 Trials of Baricitinib for Alopecia Areata

September 2023 in “Journal of The American Academy of Dermatology”

The document's conclusion cannot be provided because the content is not available.

research A Technique for Reconstruction of Eyebrows and Eyelashes

15 citations , May 2005 in “Seminars in Plastic Surgery”

The document concludes that hair follicular unit transplantation is an effective method for eyebrow and eyelash reconstruction, with patients happy despite needing regular trimming.